KRAS and non-small cell lung carcinoma: Previous studies showed that combination therapy with BA and sorafenib showed a potent and synergistic inhibitory effect on the proliferation of cancer cells such as non-small cell lung cancer (NSCLC), A549, H358, and A427 with different KRAS mutations.